Eiger BioPharmaceuticals, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
9.20
|
|
Average Rating
|
5.00
|
|
# Strong Buys
|
5
|
|
# Buys
|
0
|
|
# Holds
|
0
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-0.52
|
-0.62
|
-0.10
|
-19.23%
|
|
2022-06-30
|
-0.61
|
-0.51
|
0.10
|
16.39%
|
|
2022-03-31
|
-0.64
|
-0.64
|
0.00
|
0.00%
|
|
2021-12-31
|
-0.64
|
-0.64
|
0.00
|
0.00%
|
|
2021-09-30
|
-0.56
|
-0.65
|
-0.09
|
-16.07%
|
|
2021-06-30
|
-0.55
|
-0.57
|
-0.02
|
-3.64%
|
|
2021-03-31
|
-0.02
|
0.85
|
0.87
|
4350.00%
|
|
2020-12-31
|
0.25
|
-0.57
|
-0.82
|
-328.00%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-1.77
|
|
2021-12-31
|
-1.01
|
|
2020-12-31
|
-2.31
|
|
2019-12-31
|
-3.09
|
|
2018-12-31
|
-3.78
|
|
2017-12-31
|
-4.86
|
|
2016-12-31
|
-37.21
|
|
2014-12-31
|
-27.90
|
|
2013-12-31
|
-116.55
|